2024-12-31-accounts

THE HPV AND ANAL CANCER FOUNDATION LIMITED

TRUSTEES REPORT AND FINANCIAL STATEMENTS FOR THE YEAR ENDED 31[st] DECEMBER 2024

REGISTERED COMPANY NO: 07955451 (England and Wales) REGISTERED CHARITY NO: 1147457

THE HPV AND ANAL CANCER FOUNDATION LIMITED

TRUSTEES REPORT

AND FINANCIAL STATEMENTS

FOR THE YEAR ENDED 31 DECEMBER 2024

CONTENTS

	Page
Reference and Administrative Details	1
Report of the Trustees	2-14
Independent Examiners' report	15
Statement of Financial Activities	16
Balance Sheet	17
Statement of Cash Flow	18
Notes to the Financial Statements	19-26

THE HPV AND ANAL CANCER FOUNDATION LIMITED REPORT OF THE TRUSTEES FOR THE YEAR ENDED 31 DECEMBER 2024

Reference and Administrative Details For the Year ended 31 December 2024

LEGAL AND ADMINISTRATIVE INFORMATION

TRUSTEES	C Almada
	J Almada
	T Almada
	C Levett
REGISTERED OFFICE	128 City Road
	London
	EC1V 2NX
REGISTERED COMPANY
NUMBER	07955451 (England and Wales)
REGISTERED CHARITY
NUMBER	1147457
INDEPENDENT
EXAMINER	Richard Billinghurst
	Knox Cropper LLP
	65 Leadenhall Street
	London
	EC3A 2AD
SOLICITORS	Stone King
	London
	EC1M 4BS
BANKERS	HSBC
	16 King Street Covent Garden
	London
	WC2E 8JF

1

THE HPV AND ANAL CANCER FOUNDATION LIMITED REPORT OF THE TRUSTEES FOR THE YEAR ENDED 31 DECEMBER 2024

STRUCTURE, GOVERNANCE AND MANAGEMENT

The HPV and Anal Cancer Foundation Limited is a United Kingdom (UK) subsidiary of The HPV and Anal Cancer Foundation in the United States of America (USA) (Charity EIN: 27-3217520), which was established April 2010. All work undertaken by the UK Foundation is in collaboration with its parent.

The HPV and Anal Cancer Foundation Limited is a charitable company limited by shares, incorporated in the UK on the 20th February 2012 and registered as a charity on the 25th May 2012. The company was established through its Articles of Association, which established the objects and powers of the charitable company. All shares in the company are owned by The HPV and Anal Cancer Foundation in the USA.

The HPV and Anal Cancer Foundation board consists of four members. The directors are responsible for the legal, financial, program and management oversight of the charity. The board held its annual meeting on December 30. The daily responsibilities and mission of the Foundation are executed by the teams in the USA and the UK. In the latter, the UK CEO is responsible for the coordination of day-to-day activities.

When the Trustees advertise for new board members, candidates are sourced from the general public. A diverse mix of skills and backgrounds are sought. Prospective trustees are interviewed prior to appointment. As part of their induction, new trustees are given an overview of the work of The HPV and Anal Cancer Foundation in addition to

Risk Management

systems are in place to mitigate those risks which the charity may face.

FINANCIAL REVIEW

It is important to note that the parent and subsidiary organizations operate as one entity in achieving the mission of the organisation. The revenue for the charity is dependent on donations from the public. Income for the UK HPV and Anal Cancer Foundation in 2024 was £63,948 and expenditure was £168,988.

Total free reserves at the year end amounted to £176,615.

Reserves Policy

The Trustees have reviewed the amount of reserves it regards as a minimum prudent requirement. They have concluded that provision for three months operating reserves that enable the organisation to meet its financial commitments including grants, contracts and staff salaries is sufficient. This would allow time to manage cost reductions or generate funds as required whilst minimising the impact on service provision. At 31 December 2024 this amounted to £32,421.

2

THE HPV AND ANAL CANCER FOUNDATION LIMITED REPORT OF THE TRUSTEES FOR THE YEAR ENDED 31 DECEMBER 2024 (continued)

OBJECTIVES, ACTIVITIES AND ACHIEVEMENTS

Public Benefit

History

The Foundation was first established in the USA in 2010 by three siblings who lost their mother, aged 53, to stage IV HPV-related anal cancer. Frustrated by the limited therapeutic and community support available to her, they created the organisation to fill the void caused by scant public, scientific and medical focus on this disease and its cause, the human papillomavirus (HPV). HPV causes anal cancer and at least five other cancers, amounting to 5% of cancers worldwide. These cancers are preventable. In 2012, the organization expanded to the UK with 2013 as its first full operational year.

Mission

The HPV and Anal Cancer Foundation empowers anal cancer patients and accelerates prevention and research methods that eliminate anal cancer and the virus that causes the majority of cases, HPV.

Objectives

• Highlight the relevance of human papillomavirus (HPV) in contracting cancer;

• Advocate for prevention methods that will end anal cancer and HPV-related cancers, including gender-neutral vaccination;

• Accelerate a cure for the 5% of all cancers that are caused by HPV, with a focus on anal cancer; and

• Provide support for survivors, caregivers, scientists and providers connected to anal cancer.

The Need

-related

cancers. HPV is a very common skin virus that nearly every sexually active person will get at some point in their lives. HPV affects both men a of the anus, cervix, head and neck, penis, vagina, and vulva.

Protection against HPV through universal HPV vaccination is a critical public health goal. With HPV identified as a cause of six different types of cancer, and 5% of cancer cases worldwide, it is imperative that we protect the entire population against it. The most effective method to reduce cancers related to HPV is to prevent initial infection of the virus through immunisation. The Foundation achieves this important aim through its efforts to advance equal access to HPV protection for both boys and girls through gender-neutral vaccination (GNV) against the virus. At the introduction of the vaccine in most countries, only girls were able to receive this life-saving intervention while boys were generally excluded. The Foundation created and led the coalitions in the US and UK to ensure all children have equal access to protection against these cancers. The US achieved the milestone of recommending HPV protection -year advocacy campaign in the UK, school-based HPV vaccination for boys began in September 2019. Our focus is on securing the same protection for boys as well as girls across Europe, and beyond.

3

THE HPV AND ANAL CANCER FOUNDATION LIMITED REPORT OF THE TRUSTEES FOR THE YEAR ENDED 31 DECEMBER 2024 (continued)

While we work to prevent future cases, it is also fundamental that scientific and medical disparities are addressed for the population that will continue to be diagnosed with HPV-related cancers like anal cancer. Treatment options have barely progressed since the 1970s and minimal research has been undertaken in new therapies. The medical and scientific communities need better research tools and investment in novel ideas to develop a cure.

The stigma surrounding anal cancer remains one of the central challenges to improving outcomes for anal cancer patients. Unfortunately, many medical centres provide only limited information specific to the experience of anal cancer. Many patients feel isolated and lack the support and educational resources that significantly improve quality of life during and after treatment.

Strategies to Achieve Our Goals

We achieve our mission in the UK and US through collaboration with scientists, clinicians, survivors, organisations, and government agencies; education of stakeholders and the general public; survivor support; and investment in the medical and scientific community to end HPV and the cancers it causes. Specifically, we take action to destigmatize and raise awareness about HPV, HPV-related cancers, and anal cancer; increase access to the HPV vaccine; improve screening protocols and preventative care; empower anal cancer thrivers; and accelerate a cure for anal cancer and other HPV-related illnesses.

Key achievements in 2024

NOMAN is an Island: Race to End HPV

The NOMAN Campaign raises awareness about the HPV-related cancer epidemic in men and women and educates about the importance of universal HPV vaccination, while challenging participants to extreme endurance races across the world. It is through such extreme feats of athleticism that NOMEN honour the struggle and isolation that many cancer patients feel.

NOMAN has been an incredibly successful campaign. Since its inaugural event in 2013 with the Barcelona Ibiza: Row to End HPV, over 200 individuals and their hundreds of supporters have embraced the cause and our values. These NOMAN have raised awareness about HPV cancers on a local, national and international scale, as well as funds to support out programmes.

2024 was a year of remarkable progress toward our vision of a world free from HPV cancers, with new milestones bringing us closer to this goal. Seventy-six countries around the world now undertake gender-neutral HPV vaccination, protecting both their daughters and their sons against the devastation caused by this preventable virus. In 2024 we fostered new coalitions with key stakeholders in HPV advocacy and policy, created innovative resources and expanded support for communities, and engaged even more people in the fight against HPV-related cancers.

4

THE HPV AND ANAL CANCER FOUNDATION LIMITED REPORT OF THE TRUSTEES FOR THE YEAR ENDED 31 DECEMBER 2024 (continued)

HPV Action Europe Network

In 2018 and 2019 the Foundation was involved in discussions to establish an advocacy campaign in Europe to introduce gender-neutral vaccination (GNV) across the region and completely eliminate HPV-related diseases. NOMAN has partnered with the European Cancer Organisation (ECO) to achieve this mission. ECO works to reduce the burden of cancer and improve outcomes and the quality of care for patients through multidisciplinary initiatives. As the European not-for-profit federation of member organisations working in cancer, they convene oncology professional and patients to agree on policy, advocate for positive change, and be the united voice of the European cancer community.

Together with ECO, the Foundation looks forward to continuing to work with European policy makers to end the suffering caused by HPV cancers. In 2021, we achieved a major milestone by securing for the first time, a commitment to eliminate HPV cancers in Eu major success with the following achievements in 2024, including supporting advocacy work in countries that are falling behind.

The EPF/ECO HPV Prevention Policy Atlas launched in 2023 serves as a powerful advocacy tool to engage politicians and policy makers by providing information on the inequalities that exist in HPV prevention, along with recommendations for legislators to tackle HPV cancers. In 2024, we expanded from this foundation by convening organisations and individuals with direct experience of advocacy campaigns on HPV cancer elimination from a variety of countries, in order to share with each other experiences and learnings about effective advocacy campaigns on Advocating for Action on HPV: Lessons and Legacies detailing eight essential ingredients for advocacy success. This will serve as a useful resource for organisations who are beginning, or are indeed in the midst of their own campaigns to advocate for better HPV prevention policy.

In 2023, the HPV Action Network began supporting advocacy campaigns on HPV elimination in Romania, Croatia and Cancer Plan, and cervical screening programmes established in each country. Eastern European countries fall behind many other European countries in their efforts to eliminate HPV cancers, with low levels of HPV immunisation and cervical screening. Each month, the HPV Action network organises video conferences bringing together physicians, scientists, public health experts, and representatives of mothers and young people from all over the respective countries in order to address and identify opportunities for improvement.

5

THE HPV AND ANAL CANCER FOUNDATION LIMITED REPORT OF THE TRUSTEES FOR THE YEAR ENDED 31 DECEMBER 2024 (continued)

In 2024, HPV Action Now campaigns in Bulgaria, Croatia and Romania continue to unite national organisations and institutions to mobilise action on HPV vaccination, screening and public awareness. In Bulgaria, during the national t in March, the landmark announcement was made that boys will be included in the national HPV vaccination programme. This received widespread media coverage, including on broadcast TV. The third National Conference on vaccine-preventable diseases for the first time featured a dedicated HPV panel, including presentations from various specialists from the HPV Coalition. In Croatia, HPV Action Croatia has expanded to over 17 stakeholders, strengthened by the inclusion of the national Pilot Cervical Cancer Screening Program coordinator, and gained high-level political engagement through the Zagreb Declaration, and meetings with Voice of Oncology P -7 September. The initiative also presented at the 37th IUSTI congress and finalised national recommendations on HPV prevention and screening improvement. In Romania, political commitment was reinforced at the World Cancer Day event in Parliament, while a football stadium awareness uropean context.

In June, the Council of the European Union adapted a groundbreaking set of recommendations to increase vaccination rates against both the human papillomavirus (HPV) and hepatitis B virus (Hep B) and to combat cancers caused by these two viruses. This includes ensuring that vaccination against HPV and HBV is free of charge and easily accessible, improving communication about vaccination among parents and young people, combating misinformation and integrating immunisation against vaccine-preventable cancers into their national cancer plans. Whilst these recommendations are a welcome addition and show clear commitment to expanding access to prevention methods there is still opportunity for improvement such as the establishment of a target for HPV immunisation coverage in boys.

The work of the HPV Action network continues to draw insights from, and contribute valuable knowledge to PROTECT-EUROPE, an EU4Health Project that champions gender-neutral vaccination programmes in EU Member States to provide protection for everyone against cancers caused by HPV. In particular, the project provides EU Member States with guidance on communication on HPV vaccination between clinicians and young people and their parents/caregivers, developing effective public health messaging on HPV vaccination aimed at young people and their parents/caregivers and proposing innovations that improve uptake (e.g. bundling adolescent vaccines).

In 2019, GNV was a novel concept. Today, all EU member states have now begun or committed to immunising both girls and boys against HPV. In 2025 we will make the case for change in the Europe, beyond the borders of the European Union.

Learn more about the HPV and Hep B Action Network

Leading the charge for global gender-neutral HPV vaccination

In 2023, a record number of countries added boys into their HPV vaccination programmes, alongside girls. But gender-neutral HPV immunisation programmes, the most effective means we have to prevent HPV cancers, are still only utilised in the minority of programmes globally.

6

THE HPV AND ANAL CANCER FOUNDATION LIMITED REPORT OF THE TRUSTEES FOR THE YEAR ENDED 31 DECEMBER 2024 (continued)

In the past year we have seen increased vaccine supplies made available, new studies highlighting the effectiveness of gender-neutral immunisation, increased calls for inclusion on vaccine equity and gender-equality grounds, and the opportunity to speed up progress towards the elimination of cervical cancer, and in turn all HPV cancers.

Making the case for global gender-neutral HPV vaccination

In Autumn 2023 we announced a new partnership between NOMAN is an Island: Race to End HPV Campaign and -being on a global scale. Together, we are embarking on a mission to ensure global universal access to gender-neutral HPV vaccination, a vital step towards a healthier future for all.

Why is this partnership crucial? HPV-related diseases affect millions worldwide, irrespective of gender. HPV can cause a range of cancers - cervical, anal, penile, vaginal, vulvar, head and neck - as well as genital warts and recurrent respiratory papillomatosis (RRP). Yet genderstandard of protection in less than 50% of HPV vaccination programmes. In most countries with an HPV vaccination programme, only girls are vaccinated. Gender-neutral vaccination remains a controversial policy, especially for lower-income countries with very high rates of cervical cancer, and is not yet fully recommended by the World Health Organisation (WHO) or supported by GAVI.

By focusing only on the vaccination of girls to prevent cervical cancer, girls-only programmes fail to protect males sufficiently from the cancers caused by HPV. They also fail to protect unvaccinated women from infection by men, a particular problem in countries with low vaccination rates in girls. Girls-only programmes also mean that they unfairly shoulder the responsibility for prevention. With vaccine supply increasing, single-dose programmes changing cost-effectiveness calculations and evidence showing that 21% of males have a high-risk (cancer-causing) HPV infection we believe it is time to make the case for gender-neutral vaccination on a global basis.

By advocating gender-neutral HPV vaccination, we are not only safeguarding the health of current generations, male and female, but also paving the way for a future where HPV-related cancers and diseases are relics of the past.

Publication of Boys, Men and HPV: A global call for gender-neutral HPV vaccination

Traditionally, HPV prevention programs have focused on vaccinating girls, as the majority of HPV cancer cases affect females, particularly cervical cancer. However, evidence is growing regarding the burden of HPV disease in males. To succeed in our global health efforts to eliminate cervical cancer in line with the World Health Organisation (WHO) objective, protecting males is the pragmatic solution, enabling us to accelerate elimination efforts, in addition to removing barriers to immunisation

7

THE HPV AND ANAL CANCER FOUNDATION LIMITED REPORT OF THE TRUSTEES FOR THE YEAR ENDED 31 DECEMBER 2024 (continued)

In May we headed to Geneva for the 77th World Health Assembly where we participated in several symposiums and -event roundtable cochaired by our CEO, David Winterflood, in partnership with GAMH, bringing together public health leaders and policymakers to discuss advancing GNV. During the event, we highlighted our roadmap to ending HPV cancers, discussed avenues for collaboration, and identified the key barriers to and opportunities for achieving worldwide GNV.

Boys, Men and HPV: A global call for genderat the Union for International Cancer Control (UICC) World Cancer Congress. Calling for a more ambitious and ethical approach to HPV vaccination at the global level, our goal is clear: by 2030, all countries without an HPV vaccination programme should have introduced HPV vaccination on a gender-neutral basis, while countries currently with a girls-only programme should have transitioned to GNV.

Our 6 recommendations for global and national stakeholders are:

1. HPV must be understood, and responded to, as a threat to the health of all sexes and genders.

2. GNV should be viewed from the perspective of its potential to eliminate high-risk, oncogenic HPV types, thereby accelerating the elimination of not only cervical cancer but also all the cancers caused by HPV.

3. By 2028, global policymakers should have reviewed the issue of GNV with a view to recommending its implementation. The WHO should make boys a primary target for HPV vaccination.

4. By 2030, all countries currently without an HPV vaccination programme should have introduced HPV vaccination on a gender-neutral basis while countries currently with a girls-only programme should have transitioned to GNV.

5. Health partnerships between countries with established GNV programmes and lower-income countries should be established along with capacity-building initiatives to support the wider implementation of GNV.

6. A greater focus is needed on increasing vaccine uptake to at least 90% for all, a target most likely to be achieved through school-based vaccination programmes.

GNV is no longer a novel concept. Updating WHO policy to recognise the importance of protecting both boys and girls would act as a catalyst to strengthen and accelerate progress towards the elimination of all HPV cancers. Already endorsed by over 30 organisations from around the world, this call to action is already serving as a centerpiece for our advocacy work, in order to safeguard the health of current generations, male and female, but also to pave the way for a future where HPV-related cancers and diseases are relics of the past.

8

THE HPV AND ANAL CANCER FOUNDATION LIMITED REPORT OF THE TRUSTEES FOR THE YEAR ENDED 31 DECEMBER 2024 (continued)

Shaping the global conversation around HPV prevention

We continue to inform the discussion around HPV and its connection to cancers in males as well as females, and why protecting everyone is vital if we are to eliminate all HPV cancers. Throughout 2024, NOMAN presented and participated at forums across the globe including:

• The Cervical Cancer Elimination Initiative (CCEI) third partners meeting at WHO in the Palais des Nations, Geneva. Discussions focused on policy and advocacy, innovation and implementation, and general engagement strategies with global stakeholders.

• 'Co-creating priorities for cancer 2030 with people affected by cancer and emergent leaders' at the WHO, discussing opportunities to ensure that we eliminate barriers to cancer care for cancer patients and ensure that no one is left behind.

• -sectoral and Country-based

• International Papillomavirus Conference (IPVC) in Edinburgh,

• the last 14 years, in addition to providing reflections on 10 years of the Barcelona - Ibiza: Row to End HPV as a vehicle to engage the public and policymakers alike in our mission to end all HPV cancers.

• European Cancer Summit in

• Brussels, reflecting on 5 years of achievement of the HPV Action network in Europe, and sharing our new global call to action report.

• CoESMO-Asia in Singapore, bringing together prominent figures in the HPV, cancer, and public health domains from across Asia who are concerned about men's cancer incidence and mortality, and the role gender-neutral HPV vaccination can play in improving outcomes.

Anal Cancer Foundation

Anal cancer is one of the fastest growing cancers in the United States, and steadily increasing in the United Kingdom. We continue to work tirelessly to make life better for families facing anal cancer through our programs to raise awareness, accelerate early detection, improve quality of life, and advance a cure. This year, we made incredible progress raising awareness about the need to reform how anal cancer thrivers are diagnosed and treated.

Peer to Peer Support Programme and Thriver Education

In the UK, about 1,600 people, and in the US, about 10,500 are diagnosed with anal cancer annually. Anal cancer incidence is increasing and affects more people across the world every year. The social stigma that anal cancer carries prevents fair and equitable conversation, awareness, and funding to support research and care for people with the disease.

9

THE HPV AND ANAL CANCER FOUNDATION LIMITED REPORT OF THE TRUSTEES FOR THE YEAR ENDED 31 DECEMBER 2024 (continued)

Support and information is limited for anal cancer thrivers (our word for survivors) and many thrivers never meet another anal cancer patient. The Foundation provides educational forums and a peer mentoring program to support thrivers to close this gap. The Peer to Peer Support Program is a free service provided by the Foundation in the UK and USA to connect patients and caregivers facing the challenges brought on by anal cancer with a peer who has undertaken the same journey.

Connections are available for anyone at any cancer stage from newly diagnosed to years after treatment. Volunteers listen and help thrivers through their cancer journey by sharing their own experiences on treatment, stigma and social experiences relating t

affected by anal cancer and give survivors a voice and a community. The program also matches caregivers together. ram included 1,300 thrivers, caregivers, and peer mentors.

event, featuring expert clinicians who treat people living with anal cancer as well as a panel of thrivers has been viewed by over 6,500

of the year.

International Anal Neoplasia Society (IANS)

IANS, the International Anal Neoplasia Medical Society, creates medical guidelines and supports research essential to preventing and treating anal cancer. IANS was created with a seed grant from the Foundation.

IANS mission is to provide a forum for individuals with a broad spectrum of background, viewpoints and geographic origin, an exchange of ideas and dissemination of knowledge regarding the pathogenesis, diagnosis, treatment and prevention of anal neoplasia.

In support of this mission IANS:

• Develops position papers regarding the pathogenesis, diagnosis, treatment and prevention of anal neoplasia. Represents the consensus opinion of IANS regarding the above topics to other professional societies, public organizations, regulatory authorities and governmental bodies.

• Encourages the development of a robust research agenda on the pathogenesis, diagnosis, treatment and prevention of anal neoplasia.

• Develops educational materials and conduct training courses that encourage the entry of a broad spectrum of clinicians into the field of anal neoplasia, and that furthers the development and depth of skills of clinicians needed to optimally diagnose, treat and prevent anal neoplasia.

• Develop educational materials for patients with anal neoplasia.

UK CEO David Winterflood has been invited to present at the upcoming 2025 symposium as part of a panel on anal cancer screening, and will highlight the importance of DAREs by HCPs for patients presenting symptoms.

10

THE HPV AND ANAL CANCER FOUNDATION LIMITED REPORT OF THE TRUSTEES FOR THE YEAR ENDED 31 DECEMBER 2024 (continued)

Information and Connection

support, and inspiration for patients and families affected by anal cancer.

Our focus is ensuring patients get the information and support they need during their anal cancer journey. Our section features information for patients at all stages of the anal cancer journey from newly diagnosed to post-treatment resources, such as how physical therapy can help with anal cancer treatment recovery. The site is the most comprehensive source of information on side effects and side effect mitigation during and after anal cancer treatment. This digital hub is populated experiences), information about helpful medical resources, and professional medical bodies, as well as connections to other patients and caregivers through our Peer-to-Peer Support Program.

Our goal in 2024 continued to be ensuring that more anal cancer thrivers have access to the information they need to face their cancer journey through targeted outreach based on our existing supporter base and a newsletter series for patients and caregivers, focused on our expert and popular resources. Our communications strategy continues to focus on consistency and providing useful information, with content covering treatment and research updates, stories from community members, and explainers of our services and how we support the anal cancer community.

The continued investment into our digital resources is continuing to pay dividends. Organic and direct traffic to the website has increased by 13% and 3% respectively vs the previous year. The significant increases in both of these metrics, indicate that despite the threats and challenges posed by AI to internet search, users still value authoritative and trustworthy resources when it comes to their health. We will continue to refine our online content to ensure that our information and content is of the highest quality.

In 2024, we also undertook several webinars. On Anal Cancer Awareness Day, fellow anal cancer thrivers shared their personal experiences advocating for themselves during their anal cancer journeys. Whether it be how the patient negotiated for a different treatment, demanded a second opinion, requested a referral for supportive services, or simply shared their story for the world to hear, these provided moments of inspiration and vulnerability to connect our community. We also undertook the latest instalments of our expert hour series in the autumn. Dr. Van Morris from MD Anderson talked us through the role of circulating tumor DNA (ctDNA), a blood-based test which is changing how we manage and monitor cancers like colorectal and anal. This technology could help us detect which patients are at higher risk for recurrence, providing a new edge in the fight to cure more patients. Dr presence three months after chemoradiation was associated with an increased risk of cancer recurrence. We also hosted a webinar exploring fertility preservation options during anal cancer treatment. Led by reproductive endocrinologist Dr Alexander Kotlyar and urologist Dr Jacob Khurgin who led an important discussion about the impacts of anal cancer treatment on fertility for both men and women, featuring an engaged Q&A session. Several hundred attendees attended the sessions and for those unable to join live, the session are published on our YouTube channel and have been viewed over 1,000 times in the short period following their publication.

11

THE HPV AND ANAL CANCER FOUNDATION LIMITED REPORT OF THE TRUSTEES FOR THE YEAR ENDED 31 DECEMBER 2024 (continued)

• 185 new anal cancer thrivers and caregivers signing up to be matched through the Peer-to-Peer Support Program.

• 230 anal cancer thrivers and caregivers helped by the 1:1 Patient Navigation Service.

• 14 thrivers sharing their story publicly with our community through our Share Your Story Initiative.

• 650+ people participating in our informational forums.

Overall, in 2024, ACF directly served over 1,000 anal cancer patients through our best-in-class patient programs, at no cost to them. Going forward, we will continue working to provide all the support the anal cancer community needs.

Looking Ahead: 2025

As we look ahead, the HPV and Anal Cancer Foundation continues to seek the most effective methods to prevent HPV and cure the cancers it causes.

The Foundation will continue to work tirelessly to eliminate all HPV-related cancers by furthering public policy and scientific debate, eliciting further professional and expert support, encouraging the development of regional initiatives on vaccinating boys, and demonstrating why it is important to protect all children against HPV at the recommended age.

Our advocacy efforts in Europe with the European Cancer Organisation and HPV Action Network to attain gender neutral HPV vaccination across the continent, continue apace. With the EU Beating Cancer Plan specifically including actions on HPV cancers within its remit, we have a mandate to gain support and empower stakeholders within member states to eliminate HPV cancers. With over 40% of cancers in the region preventable, the extension of HPV vaccination programmes to protect boys as well as girls provides a recognised and effective means to tackle cancer. By continuing to build our evidence base, seeking and identifying barriers to uptake in EC member countries, ups in member states, we are confident that more countries will sign up to gender neutral protection initiatives. An early A Shared Vision for South East Europe: Eliminating HPV Cancers Together January and provide a forum to discuss challenges and opportunities in combating HPV cancers across countries in the region including Albania, Bosnia & Herzegovina, Montenegro and Serbia.

Additionally, we will build on these national and regional endeavours, by furthering our global campaign work in -based case for global GNV including launching a joint statement supported by over 100 distinguished global health experts advocating for cancer prevention in males, conducting side events at pre-eminent health gathering such as the World Health Assembly and IPVC, hosting a series of policy webinars exploring cancer prevention in males, and organising meetings with relevant multilateral and civil society organisation to foster dialogue and collaboration.

12

THE HPV AND ANAL CANCER FOUNDATION LIMITED REPORT OF THE TRUSTEES FOR THE YEAR ENDED 31 DECEMBER 2024 (continued)

Through the NOMAN is an Island Campaign, collaborations with advocates and legislators, media attention and athletic event participation, a broader audience is understanding the importance of protecting all children against HPV. With the NOMAN Campaign leading our HPV-advocacy initiatives, our platform is growing from which to broadcast our message. 2025 will also see the return of our flagship Barcelona Ibiza: Row to End HPV event, serving as an opportunity to galvanise both long-standing and new supporters and furthering the reach of our message to prevent 5% of cancer.

We will continue to push for legislative, research and policy changes to end anal cancer and improve the lives of those affected by it. forward to providing more touchpoints for our community in 2025. Our Peer-to-Peer support program retains its importance in supporting and empowering anal cancer survivors and caregivers.

Utilising digital and live platforms, we will reach a wider proportion of the anal cancer community, enabling patients to gain answers to the concerns they have and to connect to other anal cancer patient experiences. This will be underpinned by continued investment into our digital platforms, ensuring that we provide best-in-class information for anal cancer thrivers, and their loved ones as they face an anal cancer diagnosis.

2025 will also see the return of our patient summit, bringing together anal cancer thrivers, caretakers, and advocates with medical experts to discuss the latest in anal cancer treatment and prevention research. The intention is to learn from one another, and join in solidarity to empower all those impacted by anal cancer to thrive.

We thank all of our donors and look forward to continuing the mission to empower anal cancer patients and accelerate prevention and research methods that eliminate anal cancer and the virus that causes the majority of cases, HPV.

13

THE HPV AND ANAL CANCER FOUNDATION LIMITED REPORT OF THE TRUSTEES FOR THE YEAR ENDED 31 DECEMBER 2024 (continued)

The trustees (who are also the directors of The HPV and Anal Cancer Foundation Limited) for the purposes of company law) are responsible for preparing the Report of the Trustees and the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice), including Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland".

Company law requires the trustees to prepare financial statements for each financial year which give a true and fair view of the state of affairs of the charitable company and of the incoming resources and application of resources, including the income and expenditure, of the charitable company for that period. In preparing those financial statements, the trustees are required to

• select suitable accounting policies and then apply them consistently

• observe the methods and principles in the Charity SORP

• make judgements and estimates that are reasonable and prudent

• prepare the financial statements on the going concern basis unless it is inappropriate to presume that the charitable company will continue in business.

The trustees are responsible for keeping proper accounting records which disclose with reasonable accuracy at any time the financial position of the charitable company and to enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the charitable company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

In so far as the trustees are aware:

• there is no relevant information of which the charitable company's examiners are unaware; and

• • the trustees have taken all steps that they ought to have taken to make themselves aware of any relevant information and to establish that the examiners are aware of that information.

The independent examiner, Knox Cropper LLP, will be proposed for re-appointment at the forthcoming Annual General Meeting.

This report has been prepared in accordance with the special provisions of Part 15 of the Companies Act 2006 relating to small companies.

APPROVAL

This report was approved by the Board of Directors and Trustees on September 2025 and signed on their behalf 22 by:

T Almada - Trustee

14

INDEPENDENT EXAMINER S REPORT

TO THE TRUSTEES OF THE HPV AND ANAL CANCER FOUNDATION LIMITED

I report to the charity trustees on my examination of the accounts of the Company for the year ended 31 December 2024.

Responsibilities and basis of report

As the trustees of the charitable company (and also its directors for the purposes of company law) you are responsible You are satisfied that the accounts of the Company are not required by charity or company law to be audited and have chosen instead to have an independent examination.

Having satisfied myself that the accounts of the Company are not required to be audited under Part 16 of the 2006 carried out under section 14

the Directions given by the Charity Commission under section 145(5)(b) of the 2011 Act.

I have completed my examination. I confirm that no matters have come to my attention in connection with the examination giving me cause to believe that in any material respect:

1. accounting records were not kept as required by section 386 of the 2006 Act; or

2. the accounts do not accord with those records; or

3. the accounts do not comply with the accounting requirements of section 396 of the 2006 Act other than any independent examination; or

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the accounts to be reached.

Richard Billinghurst Knox Cropper LLP Chartered Accountants 65-68 Leadenhall Street, London, EC3A 2AD

Date:

23/09/2025

15

THE HPV AND ANAL CANCER FOUNDATION LIMITED

STATEMENT OF FINANCIAL ACTIVITIES (INCORPORATING AN INCOME AND EXPENDITURE ACCOUNT) FOR THE YEAR ENDED 31 DECEMBER 2024

				2024	2023
		Unrestricted	Restricted	Total	Total
	Notes	Funds	Funds	Funds	Funds
		£	£	£	£
INCOME AND ENDOWMENTS FROM
Donations and Legacies	2	10,711	-	10,711	122,220
Other Trading Activities	3	51,705	-	51,705	457,311
Investment Income		1,532	-	1,532	250
Total		63,948	-	63,948	579,781
EXPENDITURE ON
Raising Funds	4	13,796	-	13,796	95,515
CHARITABLE ACTIVITIES	5
Care and Support		40,707	-	40,707	47,757
Awareness Raising & Education		108,026	-	108,026	192,337
Research for a Cure		6,459	-	6,459	7,364
TOTAL		168,988	-	168,988	342,973
NET INCOME/(EXPENDITURE)		(105,040)	-	(105,040)	236,808
RECONCILIATION OF FUNDS
Total Funds Brought Forward		281,655	13,100	294,755	57,947
TOTAL FUNDS CARRIED FORWARD		£176,615	£13,100	£189,715	£294,755

16

THE HPV AND ANAL CANCER FOUNDATION LIMITED (REGISTERED COMPANY NUMBER: 07955451)

BALANCE SHEET

AS AT 31[st] DECEMBER 2024

	Notes	2024	2023
		£	£
FIXED ASSETS	12	-	-
CURRENT ASSETS	13
Debtors		-	1,791
Cash at Bank and in hand		194,936	301,944
		194,936	303,735
CREDITORS: Amounts
falling due within one year	14	(5,221)	(8,980)
NET CURRENT ASSETS		189,715	294,755
TOTAL ASSETS LESS CURRENT
LIABILITIES		189,715	294,755
NET ASSETS		£189,715	£294,755
FUNDS	16
Unrestricted Funds		176,615	281,655
Restricted Funds		13,100	13,100
TOTAL FUNDS		£189,715	£294,755

The charitable company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 31 December 2024.

The members have not required the company to obtain an audit of its financial statements for the year ended 31 December 2024 in accordance with Section 476 of the Companies Act 2006.

The trustees acknowledge their responsibilities for

• (a) ensuring that the charitable company keeps accounting records that comply with Sections 386 and 387 of the Companies Act 2006 and

• (b) preparing financial statements which give a true and fair view of the state of affairs of the charitable company as at the end of each financial year and of its surplus or deficit for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the charitable company.

These financial statements have been prepared in accordance with the provisions applicable to charitable companies subject to the small companies regime.

The financial statements were approved by the Board of Trustees and authorised for issue on September 202522 and were signed on its behalf by:

T Almada Trustee

17

THE HPV AND ANAL CANCER FOUNDATION LIMITED

STATEMENT OF CASH FLOW FOR THE YEAR ENDED 31 DECEMBER 2024

	2024	2023
	£	£
OPERATING ACTIVITIES
Net income/(expenditure) for the reporting period	(105,040)	236,808
Depreciation charge	-	-
Interest payable	-	-
Investment income	(1,532)	(250)
(Increase)/decrease in debtors	1,791	(960)
Increase/(decrease) in creditors	(3,759)	(1,683)
Net cash provided by/(used in) operating activities	(108,540)	233,915
INVESTING ACTIVITIES
Investment income	1,532	250
Purchase of equipment	-	-
Net cash provided by/(used in) investing activities	1,532	250
FINANCING ACTIVITIES
Repayment of borrowing		-
Cash inflows from new borrowing		-
Cash flows from financing activities	-	-
Change in cash and cash equivalents in the reporting period	301,944	234,165
Cash and cash equivalents at the beginning of the reporting period	(107,008)	67,779
Cash and cash equivalents at the end of the reporting period	194,936	301,944

18

THE HPV AND ANAL CANCER FOUNDATION LIMITED

NOTES TO THE ACCOUNTS

FOR THE YEAR ENDED 31[st] DECEMBER 2024

1. ACCOUNTING POLICIES

Basis of Preparation of Accounts

The financial statements of the charitable company, which is a public benefit entity under FRS 102, have been prepared in accordance with the Charities SORP (FRS 102) 'Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102), Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland' and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

Going Concern

The trustees s a going concern.

Financial Reporting Standard 102 reduced disclosure exemptions

The Charitable company has taken advantage of the following disclosure exemptions in preparing these Financial statements, as permitted by FRS 102 Financial Reporting Standard applicable in the UK and Republic of Ireland .

The requirements of Section 7 Statement of Cash Flows.

Income

All income is recognised in the Statement of Financial Activities once the charity has entitlement to the funds, it is probable that the income will be received and the amount can be measured reliably.

Expenditure

Liabilities are recognised as expenditure as soon as there is a legal or constructive obligation committing the charity to that expenditure, it is probable that a transfer of economic benefits will be required in settlement and the amount of the obligation can be measured reliably. Expenditure is accounted for on an accruals basis and has been classified under headings that aggregate all cost related to the category. Where costs cannot be directly attributed to particular headings they have been allocated to activities on a basis consistent with the use of resources.

Grants offered subject to conditions which have not been met at the year end date are noted as a commitment but not accrued as expenditure.

Tangible Fixed Assets

Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life.

Ocean rowing boat and accessories over 3 years.

Taxation

The charity is exempt from corporation tax on its charitable activities.

Fund Accounting

Unrestricted funds can be used in accordance with the charitable objectives at the discretion of the trustees.

Restricted funds can only be used for particular restricted purpose within the objects of the charity. Restrictions arise when specified by the donor or when funds are raised for particular restricted purposes.

19

THE HPV AND ANAL CANCER FOUNDATION LIMITED

NOTES TO THE ACCOUNTS (Continued)

FOR THE YEAR ENDED 31[st] DECEMBER 2024

1. ACCOUNTING POLICIES - continued

Fund Accounting

Further explanation of the nature and purpose of each fund is included in the notes to the financial statements.

Pension Costs and Other Post-Retirement Benefits

The charitable company operates a defined contribution pension scheme. Contributions payable to the pension scheme are charged to the Statemen of Financial Activities in the period to which they relate.

Judgements and Key Sources of Estimation Uncertainty.

No judgement (apart from those involving estimates) have been made in the process of applying the above accounting policies that have significant effect on amounts recognised in the financial statements.

2. GRANTS AND DONATIONS

• 3 .

4.

GRANTS AND DONATIONS
	2024	2023
	£	£
Grants	-	10,000
Donations and gift aid	10,711	112,220
	10,711	122,220
OTHER TRADING ACTIVITIES
	2024	2023
	£	£
Fundraising Events	51,705	457,311
RAISING FUNDS
Raising Donations and Legacies
	2024	2023
	£	£
Staff Costs	9,236	6,990
Development Expenses	32	32
Donor Software Subscription	3,375	3,246
Event Expenses	-	83,139
Support Costs	1,153	2,108
	13,796	95,515

RAISING FUNDS Raising Donations and Legacies

20

THE HPV AND ANAL CANCER FOUNDATION LIMITED

NOTES TO THE ACCOUNTS (Continued)

FOR THE YEAR ENDED 31[st] DECEMBER 2024

4. CHARITABLE ACTIVITIES COSTS

	Direct Costs	Grant	Support	2024
		Funding of	Costs (see	Totals
		Activities	note 7)
		(see note 6)
	£	£	£	£
Care and Support	37,306	-	3,401	40,707
Awareness Raising & Education	71,466	27,533	9,027	108,026
Research for a Cure	5,919	-	540	6,459
	114,691	27,533	12,968	155,192
	Direct Costs	Grant	Support	2023
		Funding of	Costs (see	Totals
		Activities	note 7)
		(see note 6)
	£	£	£	£
Care and Support	40,826	-	6,931	47,757
Awareness Raising & Education	158,820	22,934	10,583	192,337
Research for a Cure	3,828	-	3,536	7,364
	203,474	22,934	21,050	247,458

6. GRANTS PAYABLE

		2024	2023
		£	£
Awareness Raising & Education		27,533	22,934
The total grants paid to institutions during the year was as
follows
		2024	2023
		£	£
European Cancer Organisation		17,533	17,934
		10,000	5,000
		27,533	22,934

21

THE HPV AND ANAL CANCER FOUNDATION LIMITED

NOTES TO THE ACCOUNTS (Continued)

FOR THE YEAR ENDED 31[st] DECEMBER 2024

7. SUPPORT COSTS

PPORT COSTS
	2024	2023
	£	£
Bank charges	313	301
Pensions	-	-
Rent and rates	4,427	7,212
Insurance	277	306
Fees and subscriptions	1,331	828
Office costs	935	741
Sundries	-	400
Travel and meetings	1,018	7,658
Staff training	-	-
Consultancy fees	-	-
Conference expenses	-	-
Independent examination fee	5,820	4,980
Accountancy and legal fees	-	732
	14,121	23,158
T INCOME (EXPENDITURE)
	2024	2023
	£	£
Net Income/(Expenditure) is stated after charging/(Crediting):
Independent Examiner	5,220	4,980

8. NET INCOME (EXPENDITURE)

9.

4 nor for the

year ended 31 December 2023.

4 nor for the year ended 31

December 2023.

10. STAFF COSTS

	2024	2023
	£	£
Wages and Salaries	53,009	40,295
Social Security Costs	6,728	4,955
Other Pension Costs	1,500	1,350
	61,237	46,600

22

THE HPV AND ANAL CANCER FOUNDATION LIMITED

NOTES TO THE ACCOUNTS (Continued)

FOR THE YEAR ENDED 31[st] DECEMBER 2024

10. STAFF COSTS continued

The average monthly number of employees during the year was as follows:

	2024		2023
Average monthly employees		1		1

No employees received emoluments in excess of £60,000.

The key management personnel of the charity are those persons having authority and responsibility for planning, directing and controlling the activities of the charity, directly or indirectly, including any trustee of the charity and, in the case of the charity, includes the Director of UK Operations. Total employee benefits paid to key management personnel in the period amounted to £45,250 (2022: £47,523).

11. COMPARATIVES FOR THE STATEMENT OF FINANCIAL ACTIVITIES

	Unrestricted	Restricted
	Funds	Funds	Total Funds
			2023
INCOME AND ENDOWMENTS FROM	£	£	£
Donations and Legacies	122,220	-	122,220
Other Trading Activities	457,311	-	457,311
Investment Income	250	-	250
Total	579,781	-	579,781
EXPENDITURE ON
Raising Funds	95,515	-	95,515
Charitable Activities
Care and Support	47,757	-	47,757
Awareness Raising & Education	192,337	-	192,337
Research for a Cure	7,364	-	7,364
Total	342,973	-	342,973
NET INCOME/(EXPENDITURE)	236,808	-	236,808
RECONCILIATION OF FUNDS
Total Funds Brought Forward	44,847	13,100	57,947
TOTAL FUNDS CARRIED FORWARD	£281,655	£13,100	£294,755

23

THE HPV AND ANAL CANCER FOUNDATION LIMITED

NOTES TO THE ACCOUNTS (Continued)

FOR THE YEAR ENDED 31[st] DECEMBER 2024

12. TANGIBLE FIXED ASSETS

	Plant and
	Machinery
COST	£
At 1 January 2024 and
31 December 2024	47,250
DEPRECIATION
At 1 January 2024 and
31 December 2024	47,250
NET BOOK VALUE
At 31 December 2024
		-
At 31 December 2023
		-

13. DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR

		2024	2023
		£	£
	Gift Aid Recoverable	-	1,791
14.	CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
		2024	2023
		£	£
	Deferred Income	-	4,000
	Accrued Expenses	5,220	4,980
		5,220	8,980

24

THE HPV AND ANAL CANCER FOUNDATION LIMITED

NOTES TO THE ACCOUNTS (Continued)

FOR THE YEAR ENDED 31[st] DECEMBER 2024

15. ANALYSIS OF NET ASSETS BETWEEN FUNDS

----- Start of picture text -----
Unrestricted Restricted
Funds Funds 2024 2023
£ £ £ £
Current Assets 181,836 13,100 194,936 303,735
Current Liabilities (5,221) - (5,221) (8,980)
176,615 13,100 189,715 294,755
Unrestricted Restricted
Funds Funds 2023 2022
£ £ £ £
Current Assets 290,635 13,100 303,735 68,610
Current Liabilities (8,980) - (8,980) (10,663)
281,655 13,100 294,755 57,947
At
Brought Income Expenditure 31.12.24
forward
£ £ £ £
Unrestricted Funds
General Fund 281,655 63,948 (168,988) 176,615
Restricted Funds
Research for a Cure 13,100 - - 13,100
TOTAL FUNDS 294,755 63,948 (168,988) 189,715
Net Movement in Funds, included in the above are as follows:
Brought Income Expenditure At 31.12.23
forward
£ £ £ £
Unrestricted Funds
General Fund 44,847 579,781 (342,973) 281,655
Restricted Funds
Research for a Cure 13,100 - - 13,100
TOTAL FUNDS 57,947 579,781 (342,973) 294,755
----- End of picture text -----

16. MOVEMENT IN FUNDS

Capital Fund

The HPV and Anal Cancer Foundation Limited has shareholder capital equal to £1 and is owned by HPV and Anal Cancer Foundation, a registered charity in the United States of America, EIN 27-3217520.

Research for a Cure Fund

The Fund was set up to award grants to research which will advance development of effective treatments for anal and all HPV-related cancers.

25

THE HPV AND ANAL CANCER FOUNDATION LIMITED

NOTES TO THE ACCOUNTS (Continued)

FOR THE YEAR ENDED 31[st] DECEMBER 2024

17. RELATED PARTY DISCLOSURES

No remuneration was paid to the trustees in the year (2023: £NIL).

The trustees made no donations to the Charity during the year (2023: £35,400 there were no conditions attached to those donations).

18. GOING CONCERN

activities. The Charity currently holds a comfortable level of reserves, and its fixed costs are not significant. It has the ability to align its activities to the level of reserves available. The Trustees are optimistic about the fundraising outlook for the next twelve months.

26